Prostate cancer is the most common cancer in American men after skin cancer. Most cases grow slowly and are highly survivable — but some are aggressive, which is why the screening conversation matters.
Many prostate cancers are slow-growing and may never threaten a man's life — which is why active surveillance (close monitoring instead of immediate treatment) is now standard for low-risk disease. It spares men the side effects of treatment they may not need.
But a minority are aggressive. The art is telling them apart — using PSA trends, biopsy grade (Gleason/Grade Group), and imaging — so treatment goes to the cancers that need it.
📊 Data sourcesACS Cancer Facts & FiguresNCI SEER Stat FactsProstate cancer develops in the prostate, a small gland that makes seminal fluid. Most are adenocarcinomas. Many grow slowly and stay confined; a subset grows quickly and can spread to bone and lymph nodes.
Because slow-growing disease is so common, the goal of modern care is to identify which cancers are dangerous and treat those, while safely monitoring the rest. Early disease usually has no symptoms.
After skin cancer — about 1 in 8 men.
Many never become life-threatening.
97% 5-year survival across all stages.
Low-risk cancers are monitored, not always treated.
A risk factor raises the odds — it doesn't guarantee the disease. Many people with risk factors never develop prostate cancer, and some with none do. The point is to know your risk so you can act on what's modifiable.
Risk rises sharply after 50.
Black men have higher incidence and mortality.
A father or brother with prostate cancer doubles risk.
Inherited mutations raise risk and aggressiveness.
Higher in Western countries; diet may play a role.
Linked to more aggressive disease.
PSA screening is a conversation, not an automatic test. The USPSTF recommends men 55–69 decide with their clinician based on personal values; for higher-risk men the conversation starts earlier.
Start the discussion at 45 if you're Black or have a family history (40 with multiple affected relatives). The aim is to catch aggressive disease early while avoiding overtreatment of harmless cancers.
📊 Data sourcesUSPSTF Screening RecommendationsACS Cancer Facts & FiguresThe PSA blood test is the main screening tool — but because many prostate cancers are harmless, screening is a shared decision that weighs benefits against the risk of overdiagnosis.
Prostate cancer is less preventable than lifestyle-driven cancers, but general health habits and screening still help — especially for catching aggressive disease early.
More vegetables; limit excess red/processed meat.
Linked to lower risk of aggressive disease.
Obesity is tied to worse outcomes.
Guides when to start the PSA conversation.
Shared decision-making catches the dangerous cancers.
Associated with more aggressive disease.
Sources: American Cancer Society, NCI SEER, USPSTF (2018 PSA screening recommendation).
Most prostate cancers are slow-growing — but some aren't. Talk with your clinician about whether PSA testing is right for you, especially if you're Black or have a family history. The goal is to catch the aggressive ones early.